Childhood malignant hemangiopericytoma

disease

On this page

Also known as malignant childhood hemangiopericytomamalignant hemangiopericytomamalignant paediatric hemangiopericytomamalignant pediatric hemangiopericytoma

Summary

Childhood malignant hemangiopericytoma (MONDO:0004344) is a disease and 1 clinical trial. Top therapeutic interventions include doxorubicin hydrochloride and cixutumumab. A subtype of hemangiopericytoma, malignant — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood malignant hemangiopericytoma
Mondo ID	MONDO:0004344
DOID	DOID:7731
NCIT	C8090
UMLS	C0279983
MedGen	124686
GARD	0023947
Is cancer (heuristic)	no

Also known as: malignant childhood hemangiopericytoma · malignant hemangiopericytoma · malignant paediatric hemangiopericytoma · malignant pediatric hemangiopericytoma

Disease family

This is a subtype of hemangiopericytoma, malignant. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › pericytic neoplasm › hemangiopericytic tumor › hemangiopericytoma › hemangiopericytoma, malignant › childhood malignant hemangiopericytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00720174	PHASE1	COMPLETED	Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOXORUBICIN HYDROCHLORIDE	4	1
CIXUTUMUMAB	2	1

Drugs: Doxorubicin